News Related to Acadia Pharmaceuticals Inc.

Related coverage linked through entity extraction aliases.

ACADIA Pharma Rises on EU Recommendation for Daybue, Pipeline Progress

Jun 27, 2026

ACADIA Pharmaceuticals' stock jumped after the European Medicines Agency recommended approval of its Rett syndrome drug Daybue. The company also reported strong quarterly results and progress on its Alzheimer's disease psychosis treatment.

Congress Reauthorizes Rare Pediatric Disease Priority Review Voucher Program Through 2029

Feb 17, 2026

The Consolidated Appropriations Act of 2026 extends the FDA's authority to award rare pediatric disease priority review vouchers through September 30, 2029, restoring a key incentive for developing therapies for rare pediatric diseases.